Citadel Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-10,792
| Closed | -$40K | – | 9160 |
|
|
2017
Q4 | $40K | Sell |
10,792
-5,334
| -33% | -$21.8K | ﹤0.01% | 7698 |
|
|
2017
Q3 | $66K | Sell |
16,126
-3,361
| -17% | -$12.9K | ﹤0.01% | 7135 |
|
|
2017
Q2 | $72K | Sell |
19,487
-14,628
| -43% | -$58K | ﹤0.01% | 7006 |
|
|
2017
Q1 | $142K | Buy |
+34,115
| New | +$143K | ﹤0.01% | 6719 |
|
|
2016
Q4 | – | Sell |
-2,308
| Closed | -$23K | – | 8238 |
|
|
2016
Q3 | $23K | Sell |
2,308
-1,627
| -41% | -$11.5K | ﹤0.01% | 7014 |
|
|
2016
Q2 | $22K | Buy |
3,935
+1,639
| +71% | +$11.1K | ﹤0.01% | 6582 |
|
|
2016
Q1 | $17K | Sell |
2,296
-35,073
| -94% | -$270K | ﹤0.01% | 6525 |
|
|
2015
Q4 | $498K | Buy |
37,369
+34,310
| +1,122% | +$591K | ﹤0.01% | 4479 |
|
|
2015
Q3 | $50K | Sell |
3,059
-20,242
| -87% | -$415K | ﹤0.01% | 7591 |
|
|
2015
Q2 | $523K | Buy |
+23,301
| New | +$369K | ﹤0.01% | 4898 |
|
|
2014
Q3 | – | Sell |
-2,372
| Closed | -$46K | – | 8629 |
|
|
2014
Q2 | $46K | Sell |
2,372
-1,122
| -32% | -$19.8K | ﹤0.01% | 6803 |
|
|
2014
Q1 | $62K | Sell |
3,494
-172
| -5% | -$2.82K | ﹤0.01% | 6596 |
|
|
2013
Q4 | $39K | Sell |
3,666
-19,603
| -84% | -$219K | ﹤0.01% | 6173 |
|
|
2013
Q3 | $288K | Sell |
23,269
-27,692
| -54% | -$291K | ﹤0.01% | 4405 |
|
|
2013
Q2 | $477K | Buy |
+50,961
| New | +$655K | ﹤0.01% | 3883 |
|
Citadel Advisors's CASC Position: Q1 2018 in Review
Citadel Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 10,792 shares — an estimated $40K sold.
Citadel Advisors first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $523K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Citadel Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Citadel Advisors sold 10,792 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $40K.
- Citadel Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
- Citadel Advisors's Cascadian Therapeutics, Inc. position peaked at $523K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.